Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 71, No 5 (2021)
Review paper
Published online: 2021-10-13
View PDF Download PDF file
Get Citation

De-escalation of the systemic therapy in advanced colorectal cancer – justified clinical practice from the point of view of efficiency and safety

Aleksandra Grela-Wojewoda1, Renata Pacholczak-Madej12, Wojciech M. Wysocki345, Marek Ziobro1
DOI: 10.5603/NJO.2021.0055
·
Nowotwory. Journal of Oncology 2021;71(5):303-310.
Affiliations
  1. Maria Sklodowska-Curie National Research Institute of Oncology, Krakow Branch, Krakow, Poland
  2. Anatomy department, Jagiellonian University, Collegium Medicum, Krakow, Poland
  3. Department of General, Oncological and Vascular Surgery, 5th Military Clinical Hospital in Krakow, Poland
  4. Chair of Surgery, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
  5. Scientific Editorial Office, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Vol 71, No 5 (2021)
Review article
Published online: 2021-10-13

Abstract

Colorectal cancer is one of the most frequent malignant tumours in Poland, making up the third cause of cancer deaths both in women and in men with regards to the frequency of occurrence. The therapy of patients with high-stage colorectal cancer is palliative and should be conducted in a continual manner until the disease progression or unacceptable toxicity of treatment. By definition, palliative care aims at prolongation of the period to the exacerbation of the disease and of the overall survival with simultaneous guarantee of appropriate quality of life to the patients. A long-term use of a multidrug chemotherapy is often connected with the presence of clinically significant toxicity, therefore, de-escalation of systemic treatment is currently the subject of numerous analyses. The studies evaluating the effect of maintenance therapy on patient survival, prove that this kind of treatment makes up a valuable option in the case of patients in whom a good clinical effect is maintained with a concurrent reduction of toxicity of treatment. Especially in the context of the ongoing SARS-CoV-2 pandemic, monotherapy or less aggressive therapy should be discussed with patients.

Abstract

Colorectal cancer is one of the most frequent malignant tumours in Poland, making up the third cause of cancer deaths both in women and in men with regards to the frequency of occurrence. The therapy of patients with high-stage colorectal cancer is palliative and should be conducted in a continual manner until the disease progression or unacceptable toxicity of treatment. By definition, palliative care aims at prolongation of the period to the exacerbation of the disease and of the overall survival with simultaneous guarantee of appropriate quality of life to the patients. A long-term use of a multidrug chemotherapy is often connected with the presence of clinically significant toxicity, therefore, de-escalation of systemic treatment is currently the subject of numerous analyses. The studies evaluating the effect of maintenance therapy on patient survival, prove that this kind of treatment makes up a valuable option in the case of patients in whom a good clinical effect is maintained with a concurrent reduction of toxicity of treatment. Especially in the context of the ongoing SARS-CoV-2 pandemic, monotherapy or less aggressive therapy should be discussed with patients.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

advanced colorectal cancer; de-escalation therapy; cetuximab; panitumumab; bevacizumab

About this article
Title

De-escalation of the systemic therapy in advanced colorectal cancer – justified clinical practice from the point of view of efficiency and safety

Journal

Nowotwory. Journal of Oncology

Issue

Vol 71, No 5 (2021)

Article type

Review paper

Pages

303-310

Published online

2021-10-13

Page views

6149

Article views/downloads

537

DOI

10.5603/NJO.2021.0055

Bibliographic record

Nowotwory. Journal of Oncology 2021;71(5):303-310.

Keywords

advanced colorectal cancer
de-escalation therapy
cetuximab
panitumumab
bevacizumab

Authors

Aleksandra Grela-Wojewoda
Renata Pacholczak-Madej
Wojciech M. Wysocki
Marek Ziobro

References (43)
  1. Wojciechowska U, Didkowska J. Krajowy Rejestr Nowotworów. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii - Instytut im. Marii Skłodowskiej - Curie. http://onkologia.org.pl/raporty/.
  2. Douillard JY, Siena S, Peeters M, et al. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015; 51(10): 1231–1242.
    CrossRefPubMed
  3. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(7): 1346–1355.
    CrossRefPubMed
  4. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14): 1408–1417.
    CrossRefPubMed
  5. Janus-Szymańska G, Doraczyńska-Kowalik A, Bębenek M, et al. Fundamentals of personalised medicine in colorectal cancer. Nowotwory. Journal of Oncology. 2021; 71(1): 52–61.
    CrossRef
  6. Moore K, Persaud T, Torchia M. Embriologia i wady wrodzone. Ed.1. Edra Urban&Partner, Wrocław 2013.
  7. Bochenek A, Reicher M. Anatomia człowieka tom II. Ed. 9. Wydawnictwo Lekarskie PZWL, Warszawa 2007.
  8. Janiak A, Połowinczak-przybyłek J, Czyżykowski R, et al. Clinical significance of primary tumour location in colorectal cancer — a review. Oncol Clin Pract. 2021; 7(2): 67–73.
    CrossRef
  9. Salem ME, Weinberg BA, Xiu J, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017; 8(49): 86356–86368.
    CrossRefPubMed
  10. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol. 2017; 3(2): 194–201.
    CrossRefPubMed
  11. Chibaudel B, Tournigand C, Artru P, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006; 24(3): 394–400.
    CrossRefPubMed
  12. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009; 27(34): 5727–5733.
    CrossRefPubMed
  13. Berry SR, Cosby R, Asmis T, et al. Cancer Care Ontario's Gastrointestinal Disease Site Group. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2015; 26(3): 477–485.
    CrossRefPubMed
  14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23): 2335–2342.
    CrossRefPubMed
  15. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw. 2009; 20(4): 158–163.
    CrossRefPubMed
  16. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28): 3499–3506.
    CrossRefPubMed
  17. Gullick W. The epidermal growth factor system of ligands and receptors in cancer. Eur J Cancer. 2009; 45: 205–210.
    CrossRef
  18. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2): 127–137.
    CrossRefPubMed
  19. Barbacid M. ras Genes. Annu Rev Biochem. 1987; 56(1): 779–827.
    CrossRef
  20. Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015; 33(7): 692–700.
    CrossRefPubMed
  21. Aparicio T, Ghiringhelli F, Boige V, et al. PRODIGE 9 Investigators. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J Clin Oncol. 2018; 36(7): 674–681.
    CrossRefPubMed
  22. Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385(9980): 1843–1852.
    CrossRefPubMed
  23. Ma H, Wu X, Tao M, et al. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 2019; 98(50): e18227.
    CrossRefPubMed
  24. Chibaudel B, Bachet JB, André T, et al. Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. Int J Oncol. 2019; 54(4): 1433–1445.
    CrossRefPubMed
  25. Munemoto Y, Nakamura M, Takahashi M, et al. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer. 2019; 119: 158–167.
    CrossRefPubMed
  26. Pietrantonio F, Morano F, Corallo S, et al. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(9): 1268–1275.
    CrossRefPubMed
  27. Aranda E, García-Alfonso P, Benavides M, et al. Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study. Eur J Cancer. 2018; 101: 263–272.
    CrossRefPubMed
  28. Wasan H, Meade AM, Adams R, et al. COIN-B investigators. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014; 15(6): 631–639.
    CrossRefPubMed
  29. Cremolini C, Antoniotti C, Lonardi S, et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncol. 2018; 4(4): 529–536.
    CrossRefPubMed
  30. Jiang T, Chen H, Zheng J, et al. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. Adv Ther. 2020; 37(6): 2829–2840.
    CrossRefPubMed
  31. Chan WL, Lee VH, Siu WK, et al. Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. South Asian J Cancer. 2014; 3(3): 175–178.
    CrossRefPubMed
  32. Pfeiffer P, Sorbye H, Qvortrup C, et al. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clin Colorectal Cancer. 2015; 14(3): 170–176.
    CrossRefPubMed
  33. Besteiro A, Puty TC, Dias MS, et al. Metastatic colorectal cancer treated with FOLFOX + Cetuximab in Long Term Use protocol - Complete responses and acceptable tolerability profile - Case series. Int Arch Med. 2015.
    CrossRef
  34. Ma J, Yang QL, Ling Y. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer. BMC Cancer. 2017; 17(1): 132.
    CrossRefPubMed
  35. Potemski P, Bujko K, Rutkowski A, et al. Clinical practice guidelines for diagnosis and treatment of colon (C18) and rectosigmoid junction (C19) cancer. Oncol Clin Pract. 2020; 16(4): 183–193.
    CrossRef
  36. Van Cutsem E, Cervantes A, Nordlinger B, et al. ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii1–iii9.
    CrossRefPubMed
  37. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8): 1386–1422.
    CrossRefPubMed
  38. Wysocki PJ, Kwinta Ł, Potocki P, et al. Leczenie systemowe chorych na nowotwory lite w trakcie pandemii SARS-CoV-2—kompleksowe rekomendacje Polskiego Towarzystwa Onkologii Klinicznej. Onkol w Prakt Klin. 2020; 6: 57–68.
  39. Wysocki PJ, Kwinta Po, P Ł, et al. Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 – Stanowisko Polskiego Towarzystwa Onkologii Klinicznej. Nowotwory. 2020; 70(2): 43–46.
    CrossRef
  40. Podolak-Dawidziak M, Wojtukiewicz M, Krzemieniecki K, et al. Aktualne wytyczne dotyczące stosowania cząsteczek pobudzających erytropoezę i hematopoetycznych czynników wzrostu w przebiegu chemioterapii dorosłych chorych na złośliwe nowotwory. Onkol w Prakt Klin. 2005; 1: 157–164.
  41. Curigliano G, Banerjee S, Cervantes A, et al. Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020; 31(10): 1320–1335.
    CrossRefPubMed
  42. Esmo management and treatment adapted recommendations in the Covid-19 era: Colorectal cancer (CRC). https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gastrointestinal-cancers-colorectal-cancer-crc-in-the-covid-19-era.
  43. Program lekowy Ministerstwa Zdrowia. https://www.gov.pl/web/zdrowie/choroby-onkologiczne.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl